The leading market experts have placed a mean price target of $18.65 on Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) stock. This price level, which is estimated to be attained in one-year, indicates the mean of stock opinions given by the companies included in the First Call survey. The renowned research firms have predicted earnings of $0.26 a share for the upcoming quarter and $0.23 for the current fiscal.
The technical analysis of Sagent Pharmaceuticals, Inc. plainly substantiates that the 50-day moving average of Sagent Pharmaceuticals, Inc. is $19.45, and stock is trading $2.27 points away or +11.69% from its 50-day moving average of $19.45. Further it is trading $6.99 or +47.50% away its 200-day moving average of $14.73. Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) 52-week high is $21.88 and the 52-week low is $10.55.
This explains if the stock moves $-0.16, it will post a 52-week high. In event of +105.88% decline, a 52-week low will be hit.
Taking the valuation aspect to emphasize the valuation of Sagent Pharmaceuticals, Inc., shareholders can apply financial tool known as price-to-earnings ratio. This financial ratio assesses stock’s valuation by considering the relative expense of the stock. Following this ratio, Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) ratio came in at N/A.
The stock last ended the trading session at $21.72 and registered a market cap of $714.81M. To appraise firm’s growth, the shareholders take help of the Price-to-Earnings-Growth ratio. When a stock has a higher PEG ratio, it is suggestive of lower stock appreciation in approaching sessions. A stock comes in the group of undervalued stocks when its PEG ratio falls in between 0 and 1. Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) PEG ratio is at 2.91.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...